KRAS and cancer: Finally, ranking cancer driver mutations by their correlation with glutamine (Fig 2G) reveals that KRAS and ERBB4 have the strongest negative correlation (indicating that mutation is associated with a reduction of glutamine), and PRCC, JUN and PIK3CA mutations rank highly with an accumulation of glutamine.